drugset / Trial / NCT00362700

Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201

NCT00362700

Phase 2 Terminated 33 enrolled Bukwang Pharmaceutical
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and antiviral activity of Clevudine, when retreated to patients previously treated with Clevudine

Timeline

Start
2003-07
Primary completion
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Clevudine Small molecule